Loading...
Market
Will Rapport Therapeutics report a loss, breakeven, or profit for Q3 2024?
4
Resolution / Starting Odds
Loss • 33%
Breakeven • 34%
Profit • 33%
Rapport Therapeutics' official financial statements or SEC filings
Story
Rapport Therapeutics Prices IPO at $17 Per Share for 8 Million Shares, Raises $136 Million
Jun 7, 2024, 12:25 AM
Rapport Therapeutics Inc. (RAPP) has successfully priced its initial public offering (IPO), setting the stage for its debut on Friday. The company priced a full size deal of 8 million shares at $17 each, which is the midpoint of the expected range. The IPO has raised $136 million, and the offering is backed by prominent investors including Johnson & Johnson (JNJ). The pricing of the IPO marks a significant milestone for Rapport Therapeutics as it prepares to enter the public market.
View original story
Similar markets
Below $100M • 33%
$100M-$200M • 33%
Above $200M • 33%
Above $500 million • 50%
Below $500 million • 50%
Positive net income • 33%
Break-even • 33%
Negative net income • 33%
Profit decrease • 50%
Profit increase • 50%
Increase • 33%
Decrease • 33%
Remain stable • 34%
